Has the medication received FDA approval? Yes the FDA approved dimethyl fumarate on March 27, 2013.
|
|
- May Cross
- 8 years ago
- Views:
Transcription
1 Dimethyl Fumarate [formerly called BG-12] (Tecfidera ) CLINICIAN INFORMATION What is the medication? April 2013 Generic: Dimethyl Fumarate [formerly called BG-12] Brand name: Tecfidera The third oral medication approved by the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) Has the medication received FDA approval? Yes the FDA approved dimethyl fumarate on March 27, What are the indications and uses (e.g., in which types of MS)? Dimethyl fumarate is approved for the treatment of relapsing forms of MS. What were the findings in the pivotal trials of this medication? (For whom has it shown benefit? For whom might it prove harmful? For whom do we have no data?) Two Phase III pivotal trials were conducted and published in the New England Journal of Medicine September 20, DEFINE trial (Gold R, et al N Engl J Med. 2012;367: ) - Trial Design: In a two-year randomized, double blind, placebo-controlled trial, two doses of oral BG mg twice daily or 240 mg three times daily were compared with placebo in 1234 patients with relapsing-remitting MS aged and with entry Expanded Disability Status Scale (EDSS) score of 0 5, who had at least one clinically documented relapse in the year prior to entry, or who had at least one gadolinium-enhancing lesion on an MRI within six weeks of randomization. A subgroup of 540 patients evenly assigned to treatment allocation was included in the MRI component of the study and had MRIs at weeks 24, 48, and 96. Their demographics were similar to those of the study population as a whole. - Primary Endpoint: The primary endpoint was the proportion of patients who had a protocol-defined relapse within the two-year study period. Relapses were defined as new or recurrent neurologic symptoms of longer than 24-hour duration that were unassociated with fever or infection and were accompanied by new, objective neurologic findings. An Independent Neurologic Evaluation MS COALITION (800) x 112 emergingtherapies@ms-coalition.org 1 of 8
2 Committee assessed the reported relapses and was blinded to treatment assignment. - Secondary Endpoints: Secondary clinical endpoints included annualized relapse rates and the time to progression of disability. Disability progression was defined as a 1-point (or higher) increase on the EDSS score if the entry EDSS score was 1.0 or higher; or as a 1.5-point (or higher) increase on EDSS score if entry EDSS score was 0, with the increased score sustained for 12 weeks. Secondary MRI endpoints included number of new or enlarging T2 lesions and the number of gadolinium-enhancing lesions. - Results: 1237 subjects were randomized. Of those, 1234 received at least one dose and constituted the intention-to-treat cohort that was analyzed. Seventyseven percent of subjects completed the study. About 40% of the cohort had previously been treated with another disease-modifying agent for MS. The proportion of subjects relapsing within two years was 27% in the 240-mg-bid group, 26% in the 240-mg-tid group, and 46% in the placebo group, with relative risk reductions of 49% and 50% for the bid and tid groups, respectively, as compared with placebo; p<0.001 for both comparisons. [primary endpoint] Annualized relapse rate at 2 years was 0.17 for 240 mg bid, 0.19 for 240 mg tid, and 0.36 for placebo with relative reductions of 53% for 240 mg bid and 48% for 240 mg tid as compared with placebo; p value <0.001 for both comparisons. The proportion of patients with EDSS progression sustained for at least 12 weeks during the two-year study was 16% for 240 mg bid, 18% for 240 mg tid, and 27% for placebo, with relative risk reductions of 38% for 240 mg bid and 34% for 240 mg tid as compared with placebo; p=0.005 for bid, p=0.01 for tid. In the MRI subset, new or enlarging T2 lesions were reduced at 2 years by 85% in the 240-mg-bid group and by 74% in the 240 mg-tid group as compared with placebo; p<0.001 for both comparisons. Ninety-three percent of the 240 mg- bid group and 86% of the 240-mg-tid group had no enhancing lesions on MRI at 2 years as compared with 62% of the placebo group. CONFIRM study (Fox RJ et al. N Engl J Med 2012;367: ) - Trial Design: This was a Phase III randomized trial comparing blinded oral BG mg bid or 240 mg tid with placebo over two years. A reference active comparator group received glatiramer acetate and was rater-blinded but not subject-blinded subjects were equally and randomly allocated among the four arms. Entry criteria were identical to those of the DEFINE trial. A subset 2 of 8
3 of 681 subjects received MRI scans at baseline, 24, 48, and 96 weeks. The study was not designed or powered to test the superiority or noninferiority of BG-12 as compared with glatiramer acetate. - Primary Endpoint: The primary endpoint was annualized relapse rate at two years on the basis of protocol-defined relapses by criteria identical to those used in the DEFINE trial. An independent Neurologic Evaluation Committee that was blinded to treatment allocation reviewed relapse events. - Secondary Endpoints: Proportion of subjects relapsing within two years defined as above Time to confirmed disability progression as defined by EDSS score change sustained for at least 12 weeks as specified in the DEFINE trial Number of new or enlarging T2 lesions in the MRI subset at two years Number of new hypointense T1 lesions in the MRI subset at two years - Results: 1430 subjects with relapsing-remitting MS were randomized; 1417 received at least one dose and constituted the intention-to-treat population that was analyzed. Eighty percent completed the study. Approximately 29% had previously received disease-modifying therapy (DMT) for MS. Annualized relapse rates were 0.22 for 240 mg bid and 0.20 for 240 mg tid as compared with 0.40 for placebo, representing relative reductions of 44% and 51% for the bid and tid doses, respectively, as compared with placebo; p<0.001 for both comparisons [primary endpoint]. Annualized relapse rate for glatiramer acetate was 0.29, representing a 29% relative risk reduction as compared with placebo; p=0.01. The proportion relapsing over two years was 29% for 240 mg bid, 24% for 240 mg tid, 32% for glatiramer acetate, and 41% for placebo, representing relative risk reductions for relapse of 34% for bid (p=0.002), 45% for tid (p<0.001), and 29% for glatiramer acetate (p=0.01), respectively, when compared with placebo. Disability progression as measured by change in EDSS score occurred in 13% of each of the BG-12 groups, 16% in the glatiramer acetate group, and 17% in the placebo group. Differences between groups were not statistically significant. The mean number of new or enlarging T2 lesions at two years was reduced by 71% in the 240-mg-bid group, 73% in the 240-mg-tid group, and 54% 3 of 8
4 in the glatiramer acetate group as compared with placebo (p<0.001 for all comparisons). The mean number of new T1 hypointense lesions was reduced by 57% in the 240-mg-bid group (p<0.001), 65% in the 240-mg-tid group (p<0.001), and 41% in the glatiramer acetate group (p=0.002) as compared with placebo. The proportion of subjects without new or enlarging T2 lesions at two years was 27% for 240 mg bid, 31% for 240 mg tid, 24% for glatiramer acetate, and 12% for placebo. The proportion of subjects without new T1 hypointense lesions at two years was 39% for 240 mg bid, 44% for 240 mg tid, 34% for glatiramer acetate, and 21% for placebo. What is the mechanism of action of dimethyl fumarate and the rationale for its use in MS? This oral formulation of dimethyl fumarate (DMF) is rapidly hydrolyzed to its active metabolite, monomethyl fumarate (MMF). Although the mechanism by which the medication exerts its beneficial effect in MS is unknown, DMF and MMF have been shown to activate the nuclear factor (erythroid-derived 2)-like 2 transcriptional antioxidant pathway that protects cells, including neurons, from oxidative stress. DMF may also modulate immune cell responses by shifting dendritic cell differentiation, suppressing proinflammatory cytokine production, or inhibiting proinflammatory pathways. MMF is a nicotinic acid receptor agonist in vitro. What are the delivery route and recommended dosing? Tecfidera comes in a time-release capsule. An initial titration dose of 120 mg bid for one week (7 days) is recommended, followed by escalation to the maintenance dose of 240 mg bid. A first-month dosing kit containing medication in these doses is available. The capsule should be swallowed whole and not crushed, chewed, or opened and sprinkled on food. It may be taken with or without food; however, taking the medication with food appears to reduce the occurrence of flushing. Can this medication be used with other medications? DMTs: - Has this medication been tested in combination with other medications? No published studies have evaluated the use of DMF in combination with other MS DMTs. 4 of 8
5 Other Medications - Are there potential concerns regarding concurrent or prior use of other medications? No specific concerns were identified in the pivotal trials (DEFINE and CONFIRM) regarding concurrent or prior use of other medications. No specific concerns were identified for DMF with prior use of other MS DMTs, but 60% and 70% of the patients in DEFINE and CONFIRM, respectively, were naïve to MS DMTs at study entry. Pharmacokinetic studies have also not identified any potential drug interactions. DMF is not metabolized by the cytochrome P450 system and is primarily excreted through CO2 exhalation with minor renal and fecal contributions. How does the expected treatment effect compare with the treatment effect provided by other available medications? The CONFIRM trial (see details above) included glatiramer acetate as a reference comparator, but the study was not designed or powered to test the superiority or noninferiority of DMF as compared with glatiramer acetate. Available data do not allow firm conclusions about the relative effectiveness of DMF as compared with the other FDA-approved MS DMTs. Head-to-head comparative studies would be needed to determine relative effectiveness. What are the possible short-term adverse effects (AEs)? What is the range of severity of these AEs, and what are the recommended management strategies? AEs were similar in the two pivotal trials (DEFINE and CONFIRM) described above. AEs most commonly associated with DMF more often than placebo included flushing and gastrointestinal (GI) events, including diarrhea, nausea and vomiting, and abdominal pain, with flushing and GI events occurring in approximately 30% 40% of patients. Flushing and GI events were most common in the first month of treatment and decreased thereafter. Administration of DMF with food may reduce the incidence of flushing. Lymphopenia occurred in approximately 30% of patients taking DMF during the first year of treatment and then stabilized. Four weeks after stopping DMF, mean lymphocyte counts increased but did not reach baseline level and 6% remained below 500 x 106/ ml. Other AEs more common with DMF than with placebo were rash, pruritis, erythema, albuminuria, and elevation of aspartate aminotransferase. Most AEs were mild or moderate in severity. In the pivotal trials, gastroenteritis and gastritis were the only serious AEs other than MS relapses that occurred in two or more patients receiving DMF. 5 of 8
6 What are the known and theoretical long-range morbidity and mortality health risks? The following is known about health effects of DMF from the pivotal trials: Mean white cell counts and lymphocyte counts decreased over the first year of therapy and then stabilized. Transient increases in mean eosinophil counts were seen during the first 2 months of therapy. Overall infection incidence and serious infection incidence did not differ between DMF and placebo, and no opportunistic infections occurred. The incidence of malignant neoplasms was low and similar in the DMF and placebo groups in the DEFINE trial. No malignant neoplasms were seen in the CONFIRM trial. Elevated liver transaminase levels occurred more often with DMF (6%) than with placebo (3%), particularly during the first 6 months of therapy, in the DEFINE study, but there was no difference from placebo in the CONFIRM study; no cases of hepatic failure were reported. Proteinuria was reported more frequently with DMF than with placebo (8% in placebo group and 9% and 12% in the two DMF arms of DEFINE). No cases of renal failure were reported in either pivotal trial. The long-term risks of MS treatment with DMF are unknown. Has the FDA included any black box warnings about this medication? No. What training is recommended or required for patients and clinicians before initiating this treatment? There is no specific training required of either patient or clinician before initiating this treatment. What is the pregnancy rating for this medication? DMF has a pregnancy category C rating. Studies in laboratory animals revealed maternal reduction in body weight as well as AEs related to fetal survival, growth, sexual maturation, and neurobehavioral function. It is not known whether DMF is excreted in breast milk, and caution is advised when considering DMF for a woman who is breastfeeding. There is a pregnancy registry for women who were exposed to DMF during pregnancy. Clinicians are encouraged to request that patients enroll by calling Does this medication interact or interfere with oral contraceptives? No potential drug interactions with DMF have been identified. 6 of 8
7 Can Tecfidera be prescribed to pediatric or geriatric patients with MS? The safety and effectiveness in pediatric patients have not been established. Studies of DMF did not include sufficient numbers of patients over 65 years to determine whether they respond differently than younger patients. Has the FDA recommended or required a safety-monitoring program? What kind of safety monitoring is recommended (including prescreening, routine checkups, and laboratory tests)? The FDA has not required a safety-monitoring program, but it has recommended the following safety-monitoring procedures: Before initiating treatment with DMF, a recent complete blood count (CBC) (i.e., within 6 months) should be available. A CBC is recommended annually and as clinically indicated. Withholding treatment should be considered in patients with serious infection(s) until any infection present is resolved. Are there any recommended limits on duration of treatment with this medication? There are no recommended limits to the duration of treatment with DMF. What happens following termination of treatment with this medication? As with discontinuing any DMT, MS activity may return following the discontinuation of DMFe. What treatment options are available for patients after being treated with DMF? Other MS DMTs. What is the washout period? There is no specific washout period recommended for DMF. How can a provider identify a suboptimal treatment response? Clinical assessment, neuroimaging (MRI), and patient self-report indicative of continued MS disease activity in a patient adherent to treatment. Is the manufacturer/distributor offering any financial assistance program for patients? Biogen Idec offers comprehensive insurance and financial assistance programs, including a $10 copay program for eligible patients. Contact information: or Tecfidera.com. Are there any special considerations for this drug? Before starting therapy, a recent (with six months) CBC should be reviewed. Thereafter, the FDA recommends annual CBCs and as clinically indicated. Health care professionals should consider withholding treatment in patients with serious infections until the infections resolve. 7 of 8
8 COMMENTARY BY TEMPLATE AUTHORS Only patients with relapsing-remitting MS were enrolled in the two pivotal trials of DMT. The effect of DMT on patients with secondary progressive MS who do not have relapses is unknown. AUTHORS: Bruce Cohen, MD; June Halper, MSN, APN-C, MSCN, FAAN; Ruth Whitham, MD, FAAN EDITOR: Rosalind Kalb, PhD DISCLOSURES: Bruce A. Cohen, MD, was a member of the independent neurologic evaluation committee which blindly reviewed relapse occurring in the DMT studies. June Halper, MSN, APN-C, MSCN, FAAN, is a consultant and non-cme speaker for Acorda Therapeutics. Ruth Whitham, MD, FAAN, has no disclosures. Rosalind Kalb, PhD, has no disclosures. DISCLAIMER: The Emerging Therapies Collaborative is proud to be a source of information about multiple sclerosis. Our comments are based on published data and expert opinion, but do not represent individual therapeutic recommendations or prescriptions. For specific information and advice, consult your physician. FOR COMPLETE DISCLOSURES AND OTHER INFORMATION: Please visit our website at or us at emergingtherapies@ms-coalition.org. For additional information, healthcare professionals are invited to the National MS Society s Professional Resource Center at healthprof_info@nmss.org. 8 of 8
9 Update on Dimethyl Fumarate (Tecfidera) HEALTHCARE PROFESSIONAL INFORMATION Update Posted on December /2014: The US Food and Drug Administration (FDA) approved a change to the prescription label for dimethyl fumarate (Tecfidera) to include new information: Dosage and Administration, Dosing Information The Dosing and Administration section has been changed to include the following: Section 2.1: Dosing Temporary dose reductions to 120 mg twice a day may be considered by individuals who do not tolerate the maintenance dose. The recommended dose of 240 mg twice a day should be resumed within 4 weeks. Discontinuation of treatment with dimethyl fumarate should be considered for patients unable to tolerate the return to the maintenance dose. The incidence or severity of flushing may be reduced by taking dimethyl fumarate with food or by the administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to taking the medication. Contraindications Section 4 has changed to include the following: Dimethyl fumarate is contraindicated in patients with known hypersensitivity to dimethyl fumarate or to any of the excipients of this medication. Reactions have included anaphylaxis and angioedema. Warnings and Precautions The Warnings and Precautions section has been changed to include the following: 5.1 Anaphylaxis and Angioedema Dimethyl fumarate can cause anaphylaxis and angioedema after the first dose or at any time during treatment. Signs and symptoms have included difficulty breathing, urticaria and swelling of the throat and tongue. MS COALITION (800) x 112 emergingtherapies@ms-coalition.org 1 of 3
10 5.2 Progressive Multifocal Leukoencephalopathy (PML) A fatal case of PML occurred in a patient who received dimethyl fumarate for four years while enrolled in a clinical trial. The patient experienced prolonged lymphopenia (counts predominantly <0.5x109/L for 3.5 years) while on the medication; however the role of lymphopenia in this case is not known. The patient had no identified systemic medical conditions resulting in a compromised immune system and had no previous treatment with natalizumab (known to have an association with PML) and no concomitant treatment with an immunosuppressive or immunomodulatory medication. 5.3 Lymphopenia Dimethyl fumarate may decrease lymphocyte counts. In the pivotal trials, mean lymphocyte counts decreased by approximately 30% during the first year of treatment and then remained stable. Four weeks after stopping the medication, mean lymphocyte counts increased but did not return to baseline. 6% of dimethyl fumarate patients and <1% of placebo patients experienced lymphocyte counts <0.5x109/L. The incidence of infections did not differ between patients treated with dimethyl fumarate and those who received placebo. There was no increased incidence of serious infections in patients with lymphocyte counts <0.8x109/L or 5x109/L in controlled trials, although one patient in an extension study developed PML (see Warnings and Precautions, Section 5.2). In controlled and uncontrolled clinical trials, 2% of patients experienced lymphocyte counts <0.5x109/L for at least six months, and the majority of counts in these patients remained <0.5x109/L with continued therapy. A CBC including lymphocyte count should be obtained before initiating treatment with dimethyl fumarate, as well as six months after treatment, and every 6-12 months thereafter and as clinically indicated. Consider interruption of treatment in patients with lymphocyte counts <0.5x109/L that persist for more than six months. MS COALITION (800) x 112 emergingtherapies@ms-coalition.org 2 of 3
11 Given the potential for delay in lymphocyte recovery after discontinuation of treatment, consider following lymphocyte counts until lymphopenia is resolved. Consider withholding treatment in patients with serious infections until the infection(s) is resolved. 5.4 Flushing The following information was added to the warning about flushing: Administration of dimethyl fumarate with food may reduce the incidence of flushing. Alternatively, administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to dimethyl fumarate may reduce incidence or severity of flushing. The Emerging Therapies Collaborative will continue to post updated information as it becomes available. DISCLAIMER: The Emerging Therapies Collaborative is proud to be a source of information about multiple sclerosis. Our comments are based on published data and expert opinion, but do not represent individual therapeutic recommendations or prescriptions. For specific information and advice, consult your physician. MS COALITION (800) x 112 emergingtherapies@ms-coalition.org 3 of 3
Committee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationALEMTUZUMAB (LEMTRADA ) CLINICIAN INFORMATION
What is the medication? Generic: alemtuzumab Brand name: Lemtrada December 2014 Has the medication received US Food and Drug Administration (FDA) approval? If so, what are the indications and uses? Yes.
More informationCost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness
More informationThe submission positioned dimethyl fumarate as a first-line treatment option.
Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an
More informationTECFIDERA (dimethyl fumarate) delayed-release capsules, for oral use Initial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECFIDERA safely and effectively. See full prescribing information for TECFIDERA. TECFIDERA (dimethyl
More informationLaquinimod Polman, C. et al. Neurology 2005;64:987-991
Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationDimethyl fumarate for treating relapsing-remitting multiple sclerosis
Dimethyl fumarate for treating relapsing-remitting multiple Issued: August 2014 guidance.nice.org.uk/ta320 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
More informationDimethyl fumarate for treating relapsing remitting multiple sclerosis
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Dimethyl fumarate for treating relapsing remitting multiple sclerosis This guidance was developed using the single technology
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationTECFIDERA PRODUCT MONOGRAPH. Dimethyl fumarate delayed-release capsules. 120 mg and 240 mg. Other Nervous System Drug
PRODUCT MONOGRAPH Pr TECFIDERA Dimethyl fumarate delayed-release capsules 120 mg and 240 mg Other Nervous System Drug Biogen Idec Canada Inc. 90 Burnhamthorpe Road West, Suite 1100 Mississauga, Ontario
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationORAL MEDICATIONS FOR MS! Gilenya and Aubagio
ORAL MEDICATIONS FOR MS! Gilenya and Aubagio Champions against MS 4/20/13 Alexandra Goodyear, MD Stanford University Oral Medications Since 2010, 3 new oral medications for MS: Gilenya 2010 Aubagio 2012
More informationIMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products
Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to
More informationVersion History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More information5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationMedication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010
Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationSECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationClinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease
More informationTeriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).
Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The
More informationTYSABRI Risk Management Plan. Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc
76 TYSABRI Risk Management Plan Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc 77 Presentation Outline Overview and Goals of Plan Risk Minimization Plan Risk Assessment
More informationTwo-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis
Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple
More informationMultiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report
Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical
More informationOxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationIntegrating New Treatments: A Case Based Approach
Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide
More informationTreatment guidelines for relapsing MS and the two step approach for disease modifying therapy
Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.
More informationMS Treatments Aubagio TM
1 MSology Essentials Series Aubagio TM (teriflunomide) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Bonnie Blain Central Alberta MS Clinic, Red Deer, Alberta
More informationEconomic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or
Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated Summary In January 2007 Biogen Idec
More informationMS Treatments Gilenya
1 MSology Essentials Series Gilenya (fingolimod) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Trudy Campbell Dalhousie MS Research Unit, Capital Health, Halifax,
More informationAMPYRA (dalfampridine) Important Safety Information
NEWS RELEASE Acorda to Present New rhigm22 and AMPYRA (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 10/7/2015 ARDSLEY, N.Y.--(BUSINESS
More informationA neurologist would assess your eligibility and suitability for the DMTs.
Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.
More informationMultiple sclerosis disease-modifying drugs second line treatments
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Multiple sclerosis disease-modifying drugs second line treatments The following information should be read in conjunction
More informationIF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)
IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1 This brochure is a supplement to the
More informationNew Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationEastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families
Eastern Health MS Service Tysabri Therapy Information for People with MS and their Families The Eastern Health MS Service has developed this information for you as a guide through what will happen to you
More informationPCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15
PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man
More informationNews on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS
News on modifying diseases therapies Michel CLANET CHU Toulouse France ECTRIMS Current treatment strategies Future oral treatments Future non oral treatments Drug safety and risks CIS at risk of MS Active
More informationThe MS Disease- Modifying Medications GENERAL INFORMATION
The MS Disease- Modifying Medications GENERAL INFORMATION Current as of March 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationNew treatments in MS What s here and what s nearly here
5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationRELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010
RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines
More informationfingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK
fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK 08 August 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationUncertainty in Benefit and Risk: Tysabri (natalizumab)
Uncertainty in Benefit and Risk: Tysabri (natalizumab) Robert J. Temple, M.D. Deputy Center Director for Clinical Science Center for Drug Evaluation and Research U.S. Food and Drug Administration IOM Drug
More informationTAKING THE NEXT STEP
FOR ADULTS WITH MS TAKING THE NEXT STEP AMPYRA TREATMENT GUIDE walking better matters See the Patient Medication Guide below. About AMPYRA (dalfampridine) Extended release tablets How is AMPYRA different?
More informationMultiple Sclerosis - Relapsing and Remissioning
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationNew and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents
New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for
More informationThe MS Disease- Modifying Medications
The MS Disease- Modifying Medications National MS Society 1 Current as of January 2015. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,
More informationIssues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE May 11, 2015 SUBJECT EFFECTIVE DATE May 18, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Multiple Sclerosis Agents Pharmacy Service Leesa M. Allen, Deputy Secretary
More informationDepartment of Health. Rheynn Slaynt. Clinical Recommendations Committee
Recommendation 06/13 Department of Health Rheynn Slaynt Clinical Recommendations Committee The Isle of Man Department of Health recommend Gilenya (fingolimod) as a HIGH PRIORITY - as an option for the
More informationSummary of the risk management plan (RMP) for Cerdelga (eliglustat)
EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationTeriflunomide (Aubagio) 14mg once daily tablet
Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationGrowth in revenue from MS drugs has been driven largely by price increases over the last several years.
March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera
More informationVersion History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b
Version History Policy Title Drugs for MS.Drug facts box Interferon beta 1b for secondary progressive MS (SPMS) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationTHE 7:16 WAS ON TIME BUT MY LEGS WERE BEHIND SCHEDULE THAT S WHEN I ASKED FOR THE WALKING PILL
THE 7:16 WAS ON TIME BUT MY LEGS WERE BEHIND SCHEDULE THAT S WHEN I ASKED FOR THE WALKING PILL See page 12 for FREE* TRIAL OFFER *Limitations and restrictions apply. Actor portrayal AMPYRA (dalfampridine)
More informationPatients with confirmed relapse 111 26 (23.4 %) 104 16 (15.4 %) 1.52 [0.87; 2.67] p = 0.143 Probability of a relapse by week 96
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationRISK EVALUATION AND MITIGATION STRATEGY (REMS)
Initial REMS Approval: 9/2010 Most Recent Modification: 05/2015 0.5mg capsules Sphingosine 1-phosphate Receptor Modulator Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ 07936 RISK
More informationUpdate and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
More informationCost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide
More informationLiterature Scan: Oral Multiple Sclerosis Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
More informationTreatments-related side effects
Treatments-related side effects MS: from the diagnosis to the disease management MSc, MD, José Flores Rivera Instituto Nacional de Neurología y Neurocirugía Safety issues: beta interferon Depression/suicidal
More informationThe MS Disease- Modifying Medications
The MS Disease- Modifying Medications National MS Society 1 Current as of November 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 3/2016 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN. LYSODREN (mitotane)
More informationNHS Suffolk Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
NHS Suffolk Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationPerformance Improvement Strategies in Multiple Sclerosis. Community of Practice Audioconference Recorded December 7, 2010
Performance Improvement Strategies in Multiple Sclerosis Community of Practice Audioconference Recorded December 7, 2010 Audioconference faculty: Bruce A. Cohen, MD Director, Multiple Sclerosis Program
More informationRecruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed
Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has
More informationResources for the Primary Care Provider. Please print these out for reference
Resources for the Primary Care Provider Please print these out for reference Resources for providers American Academy of Neurology www.aan.com Provides education and resources, such as guidelines for clinical
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationLung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma
More informationNHS BOURNEMOUTH AND POOLE AND NHS DORSET
NHS BOURNEMOUTH AND POOLE AND NHS DORSET COMMISSIONING STATEMENT ON THE USE OF BETA-INTERFERON IN RELAPSING-REMITTING MULTIPLE SCLEROSIS OR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, WHERE RELAPSES ARE
More informationThe MS Disease- Modifying Drugs. Gener al information
The MS Disease- Modifying Drugs Gener al information Current as of October 30, 2009. This online version is updated as breaking news requires. If you have downloaded and printed a copy from the web, please
More informationTherapeutic Class Overview Multiple Sclerosis Agents
Therapeutic Class Overview Multiple Sclerosis Agents Therapeutic Class Overview/Summary: Several biologic response modifiers are Food and Drug Administration (FDA)- approved for the treatment of relapsing-remitting
More informationMedication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014
Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective
More informationfingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya ) SMC No. (763/12) Novartis Pharmaceuticals UK Ltd
fingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya ) SMC No. (763/12) Novartis Pharmaceuticals UK Ltd 10 February 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationEMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston
Erin-Marie Beals Phone 1-781-681-2850 September 9, 2014 EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Data include
More informationLemtrada (alemtuzumab)
Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationData include post-hoc assessments of controlled studies in relapsing MS regarding evolution of
September 10, 2014 Contact: Shikha Virdi 905-919-0200 ext. 5504 EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Data
More informationGuidance for Industry Migraine: Developing Drugs for Acute Treatment
Guidance for Industry Migraine: Developing Drugs for Acute Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More information